56741-34-5

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 5-AMINO-2-FLUOROBENZOATE is used as a key compound in the synthesis of various medicinal drugs due to its unique structure and properties. Its presence in drug production allows for the development of new and effective treatments for a range of medical conditions. METHYL 5-AMINO-2-FLUOROBENZOATE's versatility in pharmaceutical applications makes it a valuable asset in the industry.

InChI:InChI=1/C8H8FNO2/c1-12-8(11)6-4-5(10)2-3-7(6)9/h2-4H,10H2,1H3

Upstream product

• 2965-22-2 methyl 2-fluoro-5-nitro-benzoate 
• 125568-75-4 methyl 3-azido-6-fluorobenzoate 
• 109-89-7 diethylamine 
• 108-88-3 toluene 
• 56741-33-4 5-amino-2-fluorobenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 445-29-4 o-fluoro-benzoic acid 
• 7304-32-7 2-fluoro-5-nitrobenzoic acid 

Downstream Products

• 269070-10-2 5-{[5-(2-Adamantan-1-yl-ethyl)-2-cyclohexyl-1H-imidazole-4-carbonyl]-amino}-2-fluoro-benzoic Acid 
• 209222-25-3 1-[1-(2-toluoylmethyl)-2-oxo-5-pivaloyl-8-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-3-yl]-3-(3-methoxycarbonyl-4-fluorophenyl)urea 
• 4031-84-9 methyl 5-amino-2-(4-morpholino)benzoate 

Relevant academic research and scientific papers

From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4)

The mitogen-activated protein kinase (MAP) kinase 4 (MKK4) was found to be a major regulator of liver regeneration and could be a valuable drug target addressing liver related diseases by restoring its intrinsic regenerative capacity. We report on the synthesis and optimization of novel MKK4 inhibitors following a target-hopping strategy from the FDA-approved BRAFV600E inhibitor PLX4032 (8). Applying an iterative multi-parameter optimization process we carved out essential structural features yielding in compounds with a low nanomolar affinity for MKK4 and excellent selectivity profiles against the main off-targets MKK7 and JNK1, which, upon relevant inhibition, would totally abrogate the pro-regenerative effect of MKK4 inhibition, as well as against the off-targets MAP4K5, ZAK and BRAF with selectivity factors ranging from 40 to 430 for our best-balanced compounds 70 and 73.

FUSED BICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

Fused bicyclic compounds and uses thereof in medicine. In particular, provided are fused bicyclic compounds used as ASK1 active regulator and and use of the compounds in the manufacture of a drug for treating a disease regulated by ASK1. Further provided are a pharmaceutical composition and a method of treating a disease regulated by ASK1 comprising administering the compounds or pharmaceutical composition thereof.

PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.

LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS

Compounds, and methods of using the same, are provided as therapies for the treatment leucine-rich repeat kinase-2 (LRRK2)-related disorders including, but not limited to, neurodegenerative and neuroinflammatory disorders, such as Parkinson's Disease.

STEROIDAL [3, 2-C] PYRAZOLE COMPOUNDS, WITH GLUCOCORTICOID ACTIVITY

The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE

The present invention relates to compounds of general formula (I): wherein A, Y, X, n and B are as defined herein; and their use in the treatment and prevention of metabolic disorders, inflammatory conditions, allergic conditions, fever, pain including allodynia and nociception, eating disorders, cachexia, brain injuries, cancer of the genitals, sleep apnoea, cardiovascular disease, flush effect associated with nicotinic acid and related compounds or for the promotion of wound healing. Certain compounds of general formula (I) are new and the invention also relates to these compounds and to their use in medicine.

BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS

Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS

Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula (I): which are used to modulate the CCR-

Sulfonanilide derivatives and medicine

An object of the present invention is to offer an agent for curing urinary incontinence with high selectivity for the urethra. One of the compounds of the present invention is a sulfonanilide derivative having the following formula (I). STR1 The compounds

Descriptive Photochemistry of Polyfluorinated Azide Derivatives of Methyl Benzoate

The photochemistry of several polyfluorinated azide derivatives of methyl benzoate have been studied in a variety of solvents.We have photolyzed methyl 3-azido-6-fluorobenzoate, methyl 3-azido-4-fluorobenzoate, methyl 4-azido-2-fluorobenzoate, methyl 3-azido-2,4-difluorobenzoate, methyl 3-azido-2,6-difluorobenzoate, methyl 3-azido-2,4,6-trifluorobenzoate, and methyl 4-azido-2,3,5,6-tetrafluorobenzoate in toluene, cyclopentane, tetramethylethylene, diethylamine, dimethyl sulfide, dimethyl disulfide, and methanol in an attempt to capture the photogenerated reactive intermediates.Adducts were not formed in cyclopentane, dimethyl disulfide, and methanol solvents.Adducts were formed, however, but in modest yields, in the other solvents.In general the yield of adducts increases with the number of fluorine substituents present, and ortho and para fluorine substituents relative to the azide group are more effective in enhancing the yield of adducts relative to meta fluorine substitution.